AMPH Amphastar Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: AMPH

Price (delayed)

$20.86

Market cap

$993.67M

P/E Ratio

347.67

Dividend/share

N/A

EPS

$0.06

Enterprise value

$956.51M

Highlights
Amphastar Pharmaceuticals's revenue has increased by 13% YoY and by 5% QoQ
The company's gross profit rose by 10% YoY and by 6% QoQ
The EPS has soared by 100% from the previous quarter but it has plunged by 95% YoY
The net income has plunged by 95% YoY but it has soared by 78% from the previous quarter
The stock's P/E is 4.9% more than its last 4 quarters average of 331.3
Amphastar Pharmaceuticals's gross margin has decreased by 2.4% YoY
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Website: http://www.amphastar.com
Peers: MRNS

Key stats

What are the main financial stats of AMPH
Market
Shares outstanding
47.64M
Market cap
$993.67M
Enterprise value
$956.51M
Valuations
Price to earnings (P/E)
347.67
Price to book (P/B)
2.44
Price to sales (P/S)
2.69
EV/EBIT
180.07
EV/EBITDA
35.73
EV/Sales
2.6
Earnings
Revenue
$368.18M
EBIT
$5.31M
EBITDA
$26.77M
Free cash flow
$45.15M
Per share
EPS
$0.06
Free cash flow per share
$0.95
Book value per share
$8.55
Revenue per share
$7.75
TBVPS
$12.74
Balance sheet
Total assets
$645.74M
Total liabilities
$194.78M
Debt
$64.67M
Equity
$405.56M
Working capital
$173.07M
Liquidity
Debt to equity
0.16
Current ratio
2.36
Quick ratio
1.54
Net debt/EBITDA
-1.39
Margins
EBITDA margin
7.3%
Gross margin
41.1%
Net margin
0.7%
Operating margin
3.7%
Efficiency
Return on assets
0.4%
Return on equity
0.6%
Return on invested capital
1.2%
Return on capital employed
1%
Return on sales
1.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

AMPH stock price

How has the Amphastar Pharmaceuticals stock price performed over time
Intraday
2.2%
1 week
3.99%
1 month
2.71%
1 year
2.31%
YTD
3.73%
QTD
3.47%

Financial performance

How have Amphastar Pharmaceuticals's revenue and profit performed over time
Revenue
$368.18M
Gross profit
$151.46M
Operating income
$13.78M
Net income
$2.5M
Gross margin
41.1%
Net margin
0.7%
AMPH's net margin has dropped by 96% year-on-year but it has surged by 75% since the previous quarter
The net income has plunged by 95% YoY but it has soared by 78% from the previous quarter
The operating income has increased by 30% year-on-year and by 26% since the previous quarter
AMPH's operating margin is up by 19% since the previous quarter and by 16% year-on-year

Growth

What is Amphastar Pharmaceuticals's growth rate over time

Valuation

What is Amphastar Pharmaceuticals stock price valuation
P/E
347.67
P/B
2.44
P/S
2.69
EV/EBIT
180.07
EV/EBITDA
35.73
EV/Sales
2.6
The EPS has soared by 100% from the previous quarter but it has plunged by 95% YoY
The stock's P/E is 4.9% more than its last 4 quarters average of 331.3
Amphastar Pharmaceuticals's equity has increased by 7% YoY
The price to book (P/B) is 6% higher than the last 4 quarters average of 2.3 but 2.4% lower than the 5-year quarterly average of 2.5
Amphastar Pharmaceuticals's revenue has increased by 13% YoY and by 5% QoQ
AMPH's price to sales (P/S) is 10% less than its 5-year quarterly average of 3.0

Efficiency

How efficient is Amphastar Pharmaceuticals business performance
The company's return on assets has surged by 100% QoQ but it has shrunk by 96% YoY
The ROE has plunged by 96% YoY but it has soared by 50% from the previous quarter
The ROS has plunged by 93% YoY and by 7% from the previous quarter
The ROIC has dropped by 93% year-on-year

Dividends

What is AMPH's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AMPH.

Financial health

How did Amphastar Pharmaceuticals financials performed over time
AMPH's total liabilities is up by 30% year-on-year and by 7% since the previous quarter
Amphastar Pharmaceuticals's current ratio has decreased by 20% YoY and by 5% from the previous quarter
AMPH's debt is 84% smaller than its equity
Amphastar Pharmaceuticals's debt to equity has decreased by 11% YoY and by 6% from the previous quarter
Amphastar Pharmaceuticals's equity has increased by 7% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.